<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980925</url>
  </required_header>
  <id_info>
    <org_study_id>GETNE-T1913</org_study_id>
    <nct_id>NCT03980925</nct_id>
  </id_info>
  <brief_title>Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.</brief_title>
  <official_title>A Phase II Study of Platinum-doublet Chemotherapy in Combination With Nivolumab as First-line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic G3 Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Tumores Neuroendocrinos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Tumores Neuroendocrinos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centre, open label, non-randomized phase II study evaluating the
      efficacy and safety of nivolumab plus platinum-based chemotherapy in patients with advanced
      G3 NENs of the GEP tract or of UK origin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival rate at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients alive at 1-year from first dose of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>30 months</time_frame>
    <description>Response to treatment according to RECIST 1.1 criteria or iRECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>30 months</time_frame>
    <description>Percentage of patients without progression of disease (PD) calculated from the date of treatment initiation with first-line chemotherapy and nivolumab until the date of first documentation of PD as per RECIST v1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>30 months</time_frame>
    <description>Length of time between start of treatment and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive biomarkers</measure>
    <time_frame>30 months</time_frame>
    <description>Assess biochemical response in patients with baseline elevation of chromogranin A and/or enolase, IFN-γ, IL-6, IL-1,TNF-α, NSE and CGA and correlate it with clinical outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>30 months</time_frame>
    <description>Number and type of adverse events reported throughout the study period according to CTCAE 5.0 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival</measure>
    <time_frame>30 months</time_frame>
    <description>Length of time between date of evidenced response and progression of disease or death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Neuroendocrine Neoplasm</condition>
  <condition>Gastroenteropancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>Nivolumab + platinum-doublet chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction Phase: Nivolumab 360 mg IV plus Carboplatin IV (AUC=5) plus Etoposide 10mg/m2/day on days 1-3D, all every 3 weeks up to 6 cycles followed by Nivolumab 480mg for 24 months or until PD, death or toxicity.
Order of administration: Nivolumab, Carboplatin, Etoposide
Maintenance Phase Nivolumab 480 mg IV will be administered every 4 weeks (±3 days) for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).
At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).
Cycles are defined by 4 weeks or 28 days.</description>
    <arm_group_label>Nivolumab + platinum-doublet chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).
At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).
Cycles are defined by 4 weeks or 28 days.</description>
    <arm_group_label>Nivolumab + platinum-doublet chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).
At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).
Cycles are defined by 4 weeks or 28 days.</description>
    <arm_group_label>Nivolumab + platinum-doublet chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed G3 NENs originated in the gastroenteropancreatic tract (WHO 2010
             classification). Patients with a G3 NEN of unknown primary will also be eligible for
             this trial.

          -  Ki-67 &gt;20% or mitotic rate &gt; 20 per 10 HPF.

          -  Metastatic or locally advanced unresectable disease not amenable to treatment with
             curative intent.

          -  No prior systemic treatment for advanced disease nor as adjuvant therapy.

          -  Availability of fresh or archive formalin-fixed, paraffin-embedded tumor tissue for
             biomarker assessment.

          -  Patients must have clinically and/or radiographically documented measurable disease.
             At least one site of disease must be unidimensionally measurable as per RECIST 1.1.

          -  Adequate organ function as defined by the following criteria (within 7 days prior to
             enrollment):

               1. absolute neutrophil count (ANC) ≥1500 cells/mm3

               2. platelets ≥100,000 cells/mm3

               3. hemoglobin ≥9.0 g/dL

               4. AST and ALT ≤2.5 x upper limit of normal (ULN); in patients with liver metastases
                  AST and ALT ≤5.0 x ULN

               5. total bilirubin ≤1.5 x ULN

               6. serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥60 mL/min.

          -  Male or female, age ≥18 years.

          -  ECOG performance status of 0-2.

          -  Life expectancy of ≥12 weeks.

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             within 7 days prior to treatment initiation.

          -  Highly effective contraception (i.e. methods with a failure rate of less than 1 % per
             year) for both fertile, sexually active male and female subjects. Highly effective
             contraception must be used 28 days prior to first trial treatment administration, for
             the duration of trial treatment, and at least for 60 days after stopping trial
             treatment.

          -  Signed and dated informed consent document must be given according to ICH/GCP, and
             national/local regulations indicating that the patient (or legally acceptable
             representative) has been informed of all pertinent aspects of the trial prior to
             enrolment.

        Exclusion Criteria:

          -  The following endocrine tumor types may not be included: paraganglioma, adrenal,
             thyroid parathyroid or pituitary endocrine tumors. Large or small cell lung
             neuroendocrine carcinoma of the lung will also be excluded.

          -  Prior therapy with any immune checkpoint inhibitor.

          -  Major surgery, except diagnostic biopsy, in &lt;4 weeks or radiation therapy &lt;2 weeks
             prior to starting study treatment. Prior palliative radiotherapy to metastatic
             lesion(s) is permitted, provided there is at least one measurable lesion that has not
             been irradiated.

          -  Prior organ transplantation, including allogeneic stem-cell transplantation.

          -  Prior history of non-infectious pneumonitis requiring steroids or current pneumonitis.

          -  Systemic chronic steroid therapy (&gt; 10 mg/day prednisone or equivalent) or other
             immunosuppressive agents or use of any investigational drug within 28 days before the
             start of trial treatment. Short-term administration of steroids for allergic reactions
             or management of immune-related adverse events is allowed. Topical, inhaled, nasal and
             ophthalmic steroids are also allowed.

          -  Use of any live vaccines against infectious diseases within 4 weeks of initiation of
             study treatment.

          -  Known history of positive testing for Human Immunodeficiency Virus (HIV) infection,
             known history of or positive tests for Hepatitis B virus surface antigen (HBVsAg) or
             Hepatitis C ribonucleic acid (HCV RNA) indicating acute or chronic infection or other
             significant acute or chronic infections requiring medication at study entry.

          -  Active, known or suspected autoimmune disease or a documented history of autoimmune
             disease, including ulcerative colitis and Crohn's disease. (Patients with vitiligo,
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only
             requiring hormone replacement, psoriasis not requiring systemic treatment, or
             conditions not expected to recur in the absence of an external trigger are permitted
             to enroll).

          -  Active seizure disorder or evidence of brain metastases, spinal cord compression, or
             carcinomatous meningitis.

          -  A serious uncontrolled medical disorder or active infection that would impair their
             ability to receive study treatment will not be allowed to enter the study. Any of the
             following within the 12 months prior to study drug administration: myocardial
             infarction, uncontrolled angina, coronary/peripheral artery bypass graft, NYHA class &gt;
             III congestive heart failure, cerebrovascular accident or transient ischemic attack
             and 6 months for deep vein thrombosis or pulmonary embolism.

          -  Known hypersensitivity reactions to monoclonal antibodies (≥ grade 3 according to NCI
             Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 [xliii] or any past
             medical history of anaphylaxis or uncontrolled asthma (i.e., 3 or more asthma
             characteristics partially controlled).

          -  Any other prior malignancy within 5 years of study entry, with the exception of
             adequately treated in-situ carcinoma of the cervix, breast or uteri, or
             non-melanomatous skin cancer.

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule; those conditions
             should be discussed with the patient before registration in the trial.

          -  Dementia or significantly altered mental status that would prohibit the understanding
             or rendering of informed consent and compliance with the requirements of this
             protocol.

          -  Female patients who are pregnant or lactating, or men and women of reproductive
             potential not willing or not able to employ an effective method of birth
             control/contraception to prevent pregnancy during treatment and for 6 months after
             discontinuing study treatment The definition of effective contraception should be in
             agreement with local regulation and based on the judgment of the principal
             investigator or a designated associate.

          -  Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and in
             the judgment of the investigator would make the patient inappropriate for study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rocío García-Carbonero, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria del Carmen Riesco-Martínez, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Nepote</last_name>
    <phone>+34 93 434 44 12</phone>
    <email>investigacion@mfar.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Verónica Roca</last_name>
    <phone>+34 93 434 44 12</phone>
    <email>investigacion@mfar.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, M.D., PhD</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Cintia Hierro Carbó, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia l'Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, M.D., PhD</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Alex Teulé Vega, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, M.D., PhD</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Jaume Capdevila Castillón, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, MD., Ph.D.</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Rocio Garcia Carbonero, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Ana Belén Custodio Carretero, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, M.D., Ph.D.</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Teresa Alonso Gordoa, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, M.D., PhD</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Enrique Grande Pulido, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, M.D., PhD</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Isabel Sevilla García, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, M.D., PhD</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Paula Jiménez Fonseca, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, M.D., PhD</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Carlos López López, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, M.D., PhD</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Marta Benavent Viñuales, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Clinical Research, M.D., PhD</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Vicente Alonso Orduña, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

